Northwest Biotherapeutics Inc (NWBO) Financial Statements (2024 and earlier)

Company Profile

Business Address 4800 MONTGOMERY LANE
BETHESDA, MD 20814
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,1266,96515,1699,98337222,224
Cash and cash equivalents2,1266,96515,1699,98337222,224
Other undisclosed current assets1,9992,4602,1215,5282,8281,574
Total current assets:4,1259,42517,29015,5113,20023,798
Noncurrent Assets
Operating lease, right-of-use asset4,1834,1894,8894,4894,679
Property, plant and equipment17,27813,41815,0271,040281108
Intangible assets, net (including goodwill)1,9181,9181,9181,918  
Goodwill626626626626  
Intangible assets, net (excluding goodwill)1,2921,2921,2921,292  
Other noncurrent assets3613451,036867798761
Other undisclosed noncurrent assets  2,028 9,074171 
Total noncurrent assets:23,74021,89822,87017,3885,929869
TOTAL ASSETS:27,86531,32340,16032,8999,12924,667
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:10,24410,6876,9767,3806,34815,506
Other undisclosed accounts payable and accrued liabilities10,24410,6876,9767,3806,34815,506
Debt3,94415,4037,1042,4375,8967,155
Deferred compensation liability72,566   138
Derivative instruments and hedges, liabilities94480,559106,784354,97220,21329,995
Business combination, contingent consideration, liability9,1888,6688,2328,2757,261 
Due to related parties   66393
Other undisclosed current liabilities20,8778,1224,6739,3601,41016,653
Total current liabilities:45,204126,005133,769382,42441,19469,840
Noncurrent Liabilities
Long-term debt and lease obligation20,3125,99130,38213,42311,5021,986
Long-term debt, excluding current maturities20,3125,99125,1568,5076,5881,986
Liabilities, other than long-term debt4,4544,370    
Operating lease, liability4,4544,3705,2264,9164,914
Other undisclosed noncurrent liabilities4,950 (5,226)(4,916)  
Total noncurrent liabilities:29,71610,36130,38213,42311,5021,986
Total liabilities:74,920136,366164,151395,84752,69671,826
Temporary equity, carrying amount 18,71823,060    
Equity
Equity, attributable to parent(65,773)(128,103)(123,991)(362,948)(43,567)(47,159)
Common stock1,1751,068948830614523
Common stock, share subscribed but unissued, subscriptions receivable(79)(79)(79)(79)(10)(10)
Additional paid in capital1,291,3161,164,8851,066,8731,008,665794,900775,741
Accumulated other comprehensive income (loss)1,5363,145357(1,148)8361,000
Accumulated deficit(1,359,721)(1,297,122)(1,192,090)(1,371,216)(839,907)(824,413)
Other undisclosed equity      
Total equity:(65,773)(128,103)(123,991)(362,948)(43,567)(47,159)
TOTAL LIABILITIES AND EQUITY:27,86531,32340,16032,8999,12924,667

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues1,9321,6831,0051,2912,410412
Gross profit:1,9321,6831,0051,2912,410412
Operating expenses(57,440)(68,864)(53,707)(87,896)(29,873)(41,893)
Operating loss:(55,508)(67,181)(52,702)(86,605)(27,463)(41,481)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(7,091)(37,851)231,828(443,216)7,1675,687
Interest and debt expense(5,200)(2,691)(165)(4,412)(1,941)85
Income (loss) from continuing operations before income taxes:(67,799)(107,723)178,961(534,233)(22,237)(35,709)
Income tax expense (19)     
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(67,818)(107,723)178,961(534,233)(22,237)(35,709)
Income (loss) before gain (loss) on sale of properties:178,961(534,233)(22,237)(35,709)
Other undisclosed net income5,018     
Net income (loss):(62,800)(107,723)178,961(534,233)(22,237)(35,709)
Other undisclosed net income (loss) attributable to parent2012,6911654,4121,941(85)
Net income (loss) attributable to parent:(62,599)(105,032)179,126(529,821)(20,296)(35,794)
Other undisclosed net loss available to common stockholders, basic(1,774)    (17,765)
Net income (loss) available to common stockholders, basic:(64,373)(105,032)179,126(529,821)(20,296)(53,559)
Other undisclosed net income (loss) available to common stockholders, diluted1,774 (239,347)   
Net loss available to common stockholders, diluted:(62,599)(105,032)(60,221)(529,821)(20,296)(53,559)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(62,800)(107,723)178,961(534,233)(22,237)(35,709)
Other comprehensive income (loss)(1,609)2,7881,505(1,984)(164)1,597
Comprehensive income (loss):(64,409)(104,935)180,466(536,217)(22,401)(34,112)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,573)2,6911654,4121,941(85)
Comprehensive income (loss), net of tax, attributable to parent:(65,982)(102,244)180,631(531,805)(20,460)(34,197)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: